Treatment of transfusion-dependent thalassemic patients infected with hepatitis C virus with interferon α-2b and ribavirin [1]

Hepatology

Volumn 37, Issue 1, 2003, Pages 223-

  Sherker, Averell H ^a   Senosier, Madeleine ^b   Kermack, Delia ^c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; REBETRON; VIRUS RNA;

ADULT; BLOOD CELL COUNT; BLOOD DONOR; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; DRUG TOLERABILITY; EVALUATION; FEMALE; HEMOGLOBINOPATHY; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRON OVERLOAD; LETTER; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDEROSIS; THALASSEMIA MAJOR; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; ANTIVIRAL AGENTS; BETA-THALASSEMIA; BLOOD TRANSFUSION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; RIBAVIRIN;

EID: 0037222163     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50037     Document Type: Letter

References (3)

1. Lin OS, Keeffe EB. Current treatment strategies for chronic hepatitis B and C. Ann Rev Med 2001;52:29-49.
2. REBETOL® Product Information Rev. 8/01. Schering Corporation, Kenilworth, NJ.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.